190 related articles for article (PubMed ID: 22734651)
1. Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
Ao L; Wu Y; Kim D; Jang ER; Kim K; Lee DM; Kim KB; Lee W
Mol Pharm; 2012 Aug; 9(8):2197-205. PubMed ID: 22734651
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
3. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
6. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
7. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
9. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
[TBL] [Abstract][Full Text] [Related]
10. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.
Hawley TS; Riz I; Yang W; Wakabayashi Y; Depalma L; Chang YT; Peng W; Zhu J; Hawley RG
Am J Hematol; 2013 Apr; 88(4):265-72. PubMed ID: 23475625
[TBL] [Abstract][Full Text] [Related]
11. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
[TBL] [Abstract][Full Text] [Related]
13. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
16. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
17. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Blagosklonny MV
Leukemia; 2001 Jun; 15(6):936-41. PubMed ID: 11417480
[TBL] [Abstract][Full Text] [Related]
18. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Zangari M; Berno T; Yang Y; Zeng M; Xu H; Pappas L; Tricot G; Kamalakar A; Yoon D; Suva LJ
Bone; 2014 Apr; 61():39-43. PubMed ID: 24389365
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Swift L; Jayanthan A; Ruan Y; Anderson R; Boklan J; Trippett T; Narendran A
Target Oncol; 2018 Dec; 13(6):779-793. PubMed ID: 30446871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
